Abstract
Gelatin nanoparticles derived from bovine or porcine have been developed as various types of drug delivery system, and they need to be cross-linked to maintain their physicochemical properties in aqueous environments. Although gelatin is a widely used material in pharmaceutical industries, the safety issue of animal-origin gelatins, such as transmissible mad cow disease and anaphylaxis, remains to be solved. The purpose of this study was to prepare type A gelatin (GA) nanoparticles by modified, two-step, desolvation method and compare the toxicity of the resulting GA nanoparticles with recombinant human gelatin (rHG) nanoparticles. The GA nanoparticles were characterized, and drug loading and release pattern were measured. FITC-BSA, a model protein, was efficiently loaded in the nanoparticles and then released in a biphasic and sustained release pattern without an initial burst. In particular, the cell viability of the GA nanoparticles was less than that of the rHG nanoparticles. This finding suggests that rHG nanoparticles should be considered as an alternative to animal-origin gelatin nanoparticles in order to minimize the safety problems.
Similar content being viewed by others
References
J. K. Vasir, M. K. Reddy, and V. D. Labhasetwar,Curr. Nanosci.,1, 47 (2005).
J. S. Park and Y. W. Cho,Macromol. Res.,15, 513 (2007).
K. Zwiorek, J. Kloeckner, E. Wagner, and C. Coester,J. Pharm. Pharm. Sci.,7, 22 (2005).
J. J. Marty, R. C. Oppenheim, and P. Speiser,Pharm. Acta Helv.,53, 17 (1978).
C. A. Farrugia and M. J. Groves,J. Pharm. Pharmacol.,51, 643 (1999).
S. Azarmi, Y. Huang, H. Chen, S. McQuarrie, D. Abrams, W. Roa, W. H. Finlay, G. G. Miller, and R. Löbenberg,J. Pharm. Pharmaceut. Sci.,9, 124 (2006).
J. S. Lee, J. K. Kim, S. R. Park, and Y. H. Chang,Macromol. Res.,15, 205 (2007).
http://www.fibrogen.com/programs/fg-5009/.
S. Young, M. Wong, Y. Tabata, and A. G. Mikos,J. Control. Release,109, 256 (2005).
H. C. Liang, W. H. Chang, K. J. Lin, and H. W. Sung,J. Biomed. Mater. Res.,65A, 271 (2003).
H. W. Sung, D. M. Huang, W. H. Chang, R. N. Huang, and J. C. Hsu,J. Biomed. Mater. Res.,46, 520 (1999).
Y. W. Won and Y. H. Kim,J. Control. Release,127, 154 (2008).
C. Weber, C. Coester, J. Kreuter, and K. Langer,Int. J. Pharm.,194, 91 (2000).
N. Dinauer, S. Balthasat, C. Weber, J. Kreuter, K. Langer, and H. von Briesen,Biomaterials,26, 5898 (2005).
Y. M. Jeon, T. H. Lim, S. H. Kim, J. G. Kim, and M. S. Gong,Macromol. Res.,15, 17 (2007).
C. S. Brazel and N. A. Peppas,Eur. J. Pharm. Biopharm.,49, 47 (2000).
A. K. Bajpai and J. Choubey,J. Appl. Polym. Sci.,101, 2320 (2006).
Y. Tabata and Y. Ikada,Adv. Drug. Deliver. Rev.,31, 287 (1998).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Won, YW., Kim, YH. Preparation and cytotoxicity comparison of type a gelatin nanoparticles with recombinant human gelatin nanoparticles. Macromol. Res. 17, 464–468 (2009). https://doi.org/10.1007/BF03218893
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03218893